TY - JOUR T1 - Assessment of <em>ANG</em> variants in Parkinson’s disease JF - medRxiv DO - 10.1101/2020.10.26.20191510 SP - 2020.10.26.20191510 AU - Francis P. Grenn AU - Anni Moore AU - Sara Bandres-Ciga AU - Lynne Krohn AU - Cornelis Blauwendraat AU - on behalf of the International Parkinson’s Disease Genomics Consortium (IPDGC) Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20191510.abstract N2 - Genetic risk factors are occasionally shared between different neurodegenerative diseases. Previous studies have linked ANG, a gene encoding angiogenin, to both Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Functional studies suggest ANG plays a neuroprotective role in both PD and ALS by reducing cell death. We further explored the genetic association between ANG and PD by analyzing genotype data from the International Parkinson’s Disease Genomics Consortium (IPDGC) (14,671 cases and 17,667 controls) and whole genome sequencing (WGS) data from the Accelerating Medicines Partnership - Parkinson’s disease initiative (AMP-PD, https://amp-pd.org/) (1,647 cases and 1,050 controls). Our analysis did not replicate the findings of previous studies and found no significant association between ANG variants and PD risk.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was recievedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All analysis were performed using AMP-PD data (https://amp-pd.org/) which is an AMP partnership between Foundation for the NIH (FNIH), the National Institute of Neurological Disorders and Stroke (NINDS), the Food and Drug Administration (FDA), GSK, Pfizer, Sanofi, Celgene, Verily and the Michael J. Fox Foundation (MJFF). Access and analysis of these data was approved by AMP Governance. If you have any questions or suggestions about AMP PD Knowledge Platform governance, including the policies, ethics, or rules for data sharing through the AMP PD Knowledge Platform, please email: ACT@amp-pd.org. Clinical data and biosamples used in preparation of this article were obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the Harvard Biomarker Study (HBS), the Parkinson's Progression Markers Initiative (PPMI), and the Parkinson's Disease Biomarkers Program (PDBP). The Harvard NeuroDiscovery Biomarker Study (HBS) is a collaboration of HBS investigators [full list of HBS investigator found at https://www.bwhparkinsoncenter.org/biobank/] and funded through philanthropy and NIH and Non-NIH funding sources. The HBS Investigators have not participated in reviewing the data analysis or content of the manuscript. BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF) with support from the National Institute for Neurological Disorders and Stroke (NINDS). The BioFIND Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit michaeljfox.org/biofind. Parkinson's Disease Biomarker Program (PDBP) consortium is supported by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health. A full list of PDBP investigators can be found at https://pdbp.ninds.nih.gov/policy. The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript. PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including [list the full names of all of the PPMI funding partners found at www.ppmi-info.org/fundingpartners]. The PPMI Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit www.ppmi-info.org. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata is provided in supplementary tables and code used to generate the provided data is on our github (https://github.com/ipdgc/IPDGC-Trainees/blob/master/ANG.md). https://github.com/ipdgc/IPDGC-Trainees/blob/master/ANG.md ER -